 Robert Skinner
Concepts (165)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 7 | 2020 | 526 | 0.610 |
Why?
| | Fluorocarbons | 4 | 2019 | 52 | 0.550 |
Why?
| | Brain Ischemia | 4 | 2020 | 169 | 0.540 |
Why?
| | Arousal | 4 | 2004 | 106 | 0.490 |
Why?
| | Posture | 2 | 2004 | 80 | 0.460 |
Why?
| | Motor Activity | 2 | 2004 | 247 | 0.420 |
Why?
| | Neuroprotective Agents | 3 | 2019 | 125 | 0.380 |
Why?
| | Evoked Potentials, Auditory | 7 | 2010 | 98 | 0.380 |
Why?
| | Neurons | 4 | 2010 | 486 | 0.310 |
Why?
| | Locus Coeruleus | 1 | 2005 | 12 | 0.260 |
Why?
| | Spinal Cord Injuries | 4 | 2010 | 61 | 0.250 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2005 | 394 | 0.220 |
Why?
| | H-Reflex | 4 | 2010 | 27 | 0.200 |
Why?
| | Reticular Formation | 3 | 2007 | 23 | 0.190 |
Why?
| | Thrombectomy | 1 | 2020 | 68 | 0.190 |
Why?
| | Time-to-Treatment | 1 | 2020 | 74 | 0.180 |
Why?
| | Patient Transfer | 1 | 2020 | 103 | 0.180 |
Why?
| | Physical Conditioning, Animal | 2 | 2010 | 58 | 0.170 |
Why?
| | Benzhydryl Compounds | 2 | 2010 | 75 | 0.170 |
Why?
| | Disease Models, Animal | 4 | 2012 | 1639 | 0.170 |
Why?
| | Animals | 19 | 2016 | 14385 | 0.170 |
Why?
| | Rabbits | 6 | 2016 | 425 | 0.160 |
Why?
| | Electroencephalography | 5 | 2011 | 356 | 0.160 |
Why?
| | Pedunculopontine Tegmental Nucleus | 3 | 2008 | 58 | 0.160 |
Why?
| | Cerebral Angiography | 3 | 2012 | 106 | 0.160 |
Why?
| | Reaction Time | 4 | 2011 | 227 | 0.140 |
Why?
| | Habituation, Psychophysiologic | 5 | 2011 | 31 | 0.130 |
Why?
| | Brain | 2 | 2016 | 1387 | 0.130 |
Why?
| | Intracranial Embolism | 2 | 2012 | 28 | 0.120 |
Why?
| | West Nile virus | 2 | 2010 | 5 | 0.110 |
Why?
| | Rats, Sprague-Dawley | 8 | 2010 | 1663 | 0.110 |
Why?
| | Sleep | 2 | 2005 | 188 | 0.110 |
Why?
| | Sleep, REM | 3 | 2007 | 51 | 0.110 |
Why?
| | Rats | 9 | 2010 | 3415 | 0.100 |
Why?
| | Microbubbles | 1 | 2011 | 34 | 0.100 |
Why?
| | Ultrasonic Therapy | 1 | 2011 | 40 | 0.100 |
Why?
| | Evoked Potentials, Somatosensory | 1 | 2011 | 12 | 0.100 |
Why?
| | Reflex, Stretch | 1 | 2010 | 6 | 0.100 |
Why?
| | Muscle Spasticity | 1 | 2010 | 10 | 0.100 |
Why?
| | Cold Temperature | 1 | 2011 | 53 | 0.100 |
Why?
| | West Nile Fever | 1 | 2010 | 5 | 0.100 |
Why?
| | Dopamine Agents | 1 | 2010 | 19 | 0.100 |
Why?
| | Levodopa | 1 | 2010 | 41 | 0.090 |
Why?
| | Diaphragm | 1 | 2010 | 29 | 0.090 |
Why?
| | Thrombolytic Therapy | 1 | 2011 | 127 | 0.090 |
Why?
| | Electric Stimulation | 2 | 2010 | 95 | 0.090 |
Why?
| | Male | 13 | 2020 | 27334 | 0.090 |
Why?
| | Motor Neuron Disease | 1 | 2009 | 10 | 0.090 |
Why?
| | Female | 14 | 2020 | 28441 | 0.090 |
Why?
| | Carbenoxolone | 1 | 2008 | 5 | 0.090 |
Why?
| | Mefloquine | 1 | 2008 | 5 | 0.090 |
Why?
| | Afferent Pathways | 2 | 2010 | 8 | 0.090 |
Why?
| | Cervical Vertebrae | 2 | 2010 | 65 | 0.080 |
Why?
| | Gap Junctions | 1 | 2008 | 27 | 0.080 |
Why?
| | Reflex, Abnormal | 1 | 2008 | 8 | 0.080 |
Why?
| | Drug Administration Schedule | 2 | 2019 | 401 | 0.080 |
Why?
| | Neural Inhibition | 1 | 2007 | 26 | 0.080 |
Why?
| | Receptors, Muscarinic | 1 | 2006 | 18 | 0.070 |
Why?
| | Exercise Therapy | 1 | 2008 | 123 | 0.070 |
Why?
| | Acetylcholine | 1 | 2006 | 53 | 0.070 |
Why?
| | Recovery of Function | 2 | 2019 | 222 | 0.070 |
Why?
| | Time Factors | 5 | 2019 | 3213 | 0.070 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2007 | 76 | 0.070 |
Why?
| | Receptors, Nicotinic | 1 | 2006 | 80 | 0.070 |
Why?
| | Random Allocation | 3 | 2011 | 312 | 0.070 |
Why?
| | Acupuncture Points | 1 | 2005 | 2 | 0.070 |
Why?
| | Central Nervous System Stimulants | 1 | 2008 | 255 | 0.070 |
Why?
| | Americas | 1 | 2005 | 3 | 0.070 |
Why?
| | Postmortem Changes | 1 | 2005 | 19 | 0.060 |
Why?
| | Physical Education and Training | 1 | 2005 | 27 | 0.060 |
Why?
| | Motor Vehicles | 1 | 2005 | 20 | 0.060 |
Why?
| | Combat Disorders | 1 | 2005 | 42 | 0.060 |
Why?
| | Bicycling | 1 | 2005 | 43 | 0.060 |
Why?
| | Middle Aged | 5 | 2020 | 13088 | 0.060 |
Why?
| | Cell Count | 1 | 2005 | 181 | 0.060 |
Why?
| | Efferent Pathways | 1 | 2004 | 7 | 0.060 |
Why?
| | Anesthetics, Intravenous | 1 | 2003 | 26 | 0.060 |
Why?
| | Huntington Disease | 1 | 2003 | 27 | 0.060 |
Why?
| | Propofol | 1 | 2003 | 28 | 0.060 |
Why?
| | Mesencephalon | 1 | 2003 | 16 | 0.060 |
Why?
| | Electromyography | 3 | 2010 | 150 | 0.060 |
Why?
| | Analysis of Variance | 3 | 2011 | 635 | 0.060 |
Why?
| | Humans | 11 | 2020 | 54284 | 0.060 |
Why?
| | Schizophrenia | 1 | 2004 | 276 | 0.050 |
Why?
| | Serotonin | 1 | 2003 | 159 | 0.050 |
Why?
| | Tissue Plasminogen Activator | 2 | 2011 | 124 | 0.050 |
Why?
| | Triage | 1 | 2020 | 76 | 0.050 |
Why?
| | Maximum Tolerated Dose | 1 | 2019 | 37 | 0.040 |
Why?
| | Cricetinae | 2 | 2010 | 209 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 75 | 0.040 |
Why?
| | Disability Evaluation | 1 | 2019 | 103 | 0.040 |
Why?
| | Aged | 2 | 2020 | 10054 | 0.040 |
Why?
| | Veterans | 1 | 2005 | 629 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 1476 | 0.040 |
Why?
| | Synaptic Transmission | 2 | 2008 | 95 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2019 | 742 | 0.040 |
Why?
| | Sodium Channel Blockers | 2 | 2007 | 18 | 0.040 |
Why?
| | Glutamates | 1 | 2016 | 22 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2016 | 148 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2016 | 70 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2016 | 178 | 0.040 |
Why?
| | Action Potentials | 2 | 2007 | 131 | 0.040 |
Why?
| | Adult | 5 | 2020 | 14207 | 0.030 |
Why?
| | Angiography | 1 | 2016 | 147 | 0.030 |
Why?
| | Cohort Studies | 1 | 2020 | 1543 | 0.030 |
Why?
| | Aging | 3 | 2007 | 784 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2020 | 2387 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2019 | 5604 | 0.030 |
Why?
| | Prospective Studies | 1 | 2020 | 2604 | 0.030 |
Why?
| | Arkansas | 1 | 2019 | 2100 | 0.030 |
Why?
| | Emulsions | 1 | 2011 | 27 | 0.030 |
Why?
| | Rotation | 2 | 2002 | 76 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 232 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 318 | 0.020 |
Why?
| | Torque | 1 | 2010 | 24 | 0.020 |
Why?
| | Cerebral Hemorrhage | 1 | 2011 | 102 | 0.020 |
Why?
| | Mesocricetus | 1 | 2010 | 8 | 0.020 |
Why?
| | Foot | 1 | 2011 | 50 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 2010 | 41 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 110 | 0.020 |
Why?
| | Fibrinolytic Agents | 1 | 2011 | 139 | 0.020 |
Why?
| | Brain Stem | 1 | 2010 | 46 | 0.020 |
Why?
| | Spinal Cord | 1 | 2010 | 151 | 0.020 |
Why?
| | Dopamine | 1 | 2010 | 190 | 0.020 |
Why?
| | Electrophysiological Phenomena | 1 | 2009 | 20 | 0.020 |
Why?
| | Viral Envelope Proteins | 1 | 2009 | 33 | 0.020 |
Why?
| | Ultrasonography | 1 | 2011 | 480 | 0.020 |
Why?
| | Injections | 1 | 2008 | 61 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2009 | 58 | 0.020 |
Why?
| | Radiography | 1 | 2010 | 524 | 0.020 |
Why?
| | Connexins | 1 | 2008 | 29 | 0.020 |
Why?
| | RNA, Viral | 1 | 2009 | 141 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2008 | 237 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2020 | 6432 | 0.020 |
Why?
| | Chronic Disease | 1 | 2010 | 614 | 0.020 |
Why?
| | Muscimol | 1 | 2007 | 4 | 0.020 |
Why?
| | GABA-B Receptor Antagonists | 1 | 2007 | 5 | 0.020 |
Why?
| | GABA Agonists | 1 | 2007 | 17 | 0.020 |
Why?
| | Baclofen | 1 | 2007 | 11 | 0.020 |
Why?
| | Receptors, GABA-B | 1 | 2007 | 12 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1089 | 0.020 |
Why?
| | Muscarinic Agonists | 1 | 2006 | 12 | 0.020 |
Why?
| | Muscarinic Antagonists | 1 | 2006 | 18 | 0.020 |
Why?
| | Organ Culture Techniques | 1 | 2006 | 53 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2010 | 1084 | 0.020 |
Why?
| | Nicotinic Antagonists | 1 | 2006 | 46 | 0.020 |
Why?
| | Nicotinic Agonists | 1 | 2006 | 60 | 0.020 |
Why?
| | Neural Pathways | 1 | 2007 | 97 | 0.020 |
Why?
| | Exercise | 1 | 2010 | 552 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2006 | 396 | 0.020 |
Why?
| | Quadriplegia | 1 | 2005 | 9 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2010 | 847 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2006 | 720 | 0.010 |
Why?
| | Sleep Stages | 1 | 2003 | 46 | 0.010 |
Why?
| | Acoustic Stimulation | 1 | 2003 | 99 | 0.010 |
Why?
| | Motion Sickness | 1 | 2002 | 9 | 0.010 |
Why?
| | Models, Animal | 1 | 2003 | 255 | 0.010 |
Why?
| | Vestibule, Labyrinth | 1 | 2002 | 19 | 0.010 |
Why?
| | Nausea | 1 | 2002 | 52 | 0.010 |
Why?
| | Cell Membrane | 1 | 2003 | 278 | 0.010 |
Why?
| | Young Adult | 1 | 2011 | 4318 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2003 | 1228 | 0.010 |
Why?
| | Adolescent | 1 | 2011 | 6897 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2003 | 1737 | 0.010 |
Why?
| | Pregnancy | 1 | 2003 | 2620 | 0.010 |
Why?
|
|
Skinner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|